- Home
- TCBP vs XRTX Comparison
TCBP vs XRTX Comparison
Compare TCBP & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCBP
- XRTX
- Stock Information
- Founded
- TCBP 2013
- XRTX 2011
- Country
- TCBP United Kingdom
- XRTX Canada
- Employees
- TCBP N/A
- XRTX N/A
- Industry
- TCBP Biotechnology: Biological Products (No Diagnostic Substances)
- XRTX Pharmaceuticals and Biotechnology
- Sector
- TCBP Health Care
- XRTX Health Care
- Exchange
- TCBP Nasdaq
- XRTX Nasdaq
- Market Cap
- TCBP 831.0K
- XRTX 3.0M
- IPO Year
- TCBP 2022
- XRTX N/A
- Fundamental
- Price
- TCBP $1.69
- XRTX $0.95
- Analyst Decision
- TCBP Strong Buy
- XRTX
- Analyst Count
- TCBP 1
- XRTX 0
- Target Price
- TCBP $48.00
- XRTX N/A
- AVG Volume (30 Days)
- TCBP 632.6K
- XRTX 85.7K
- Earning Date
- TCBP 11-25-2024
- XRTX 05-09-2025
- Dividend Yield
- TCBP N/A
- XRTX N/A
- EPS Growth
- TCBP N/A
- XRTX N/A
- EPS
- TCBP N/A
- XRTX N/A
- Revenue
- TCBP N/A
- XRTX N/A
- Revenue This Year
- TCBP N/A
- XRTX N/A
- Revenue Next Year
- TCBP N/A
- XRTX N/A
- P/E Ratio
- TCBP N/A
- XRTX N/A
- Revenue Growth
- TCBP N/A
- XRTX N/A
- 52 Week Low
- TCBP $1.43
- XRTX $0.82
- 52 Week High
- TCBP $523.20
- XRTX $5.81
- Technical
- Relative Strength Index (RSI)
- TCBP 28.01
- XRTX 49.61
- Support Level
- TCBP $1.43
- XRTX $0.85
- Resistance Level
- TCBP $2.19
- XRTX $1.10
- Average True Range (ATR)
- TCBP 0.28
- XRTX 0.11
- MACD
- TCBP 0.19
- XRTX 0.00
- Stochastic Oscillator
- TCBP 20.57
- XRTX 30.23
About TCBP TC BioPharm (Holdings) plc
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.